Itracobin-product-650x210-

Oral Antifungal – Itracobin

Itracobin – Trolling Fungi to End the Menace.

Itracobin

ITRACOBIN CAPSULES

Itracobin

SDDP : Solid Dispersion of Drug in Polymer

HPMC: Hydroxy Propyl Methyl Cellulose

Indications:

Itraconazole Capsule is indicated for the treatment of following conditions; Dermatomycosis, Pityriasis Versicolor, Oral Candidiasis, Onychomycosis, caused by Dermatophytes and/or Yeasts, Vulvovaginal Candidiasis.

Dosage

  • Tinea Cruris, Tinea Corporis, Tinea Manuum, Tinea Pedis and Tinea Versicolor: 200 mg/day for 7 days
  • Onychomycosis:
  • Toenails: 200mg (2 capsules) once daily for 12 consecutive weeks.
  • Fingernails: 2 treatment pulses, each consisting of 200mg bid for 1 week. The pulses are separated by a 3-week period without Itraconazole.
  • Vulvovaginal Candidiasis: 200mg bid for 1-day.

Composition:

  • Itraconazole 100/200mg Capsules.

Presentation:

  • Itracobin 100 mg and 200mg Capsules are available as hard gelatin capsules containing itraconazole pellets in 1×10’s and 1×7’s capsule pack respectively.

Side Effects:

  • Report to your physician if you have any skin reactions on the areas of your skin treated.

Tips for Prevention of Fungal infections

Drugs that are contraindicated with ITRACONAZOLE capsules;

  • Analgesics Methadone.
  • Anti-arrhythmics Disopyramide, Dronedarone, Quinidine.
  • Anticoagulants and Antiplatelet Drugs – Ticagrelor.
  • Antimigraine Drugs ergot alkaloids, such as dihydroergotamine, ergometrine (ergonovine), ergotamine, eletriptan.
  • Antineoplastics Irinotecan.
  • Antipsychotics.
  • Anxiolytics and Hypnotics.
  • lurasidone, Pimozide, Triazolam.
  • Antivirals Asunaprevir (boosted).
  • Calcium Channel Blockers Felodipine.
  • Cardiovascular Drugs, Ivabradine, Ranolazine
  • Diuretics Eplerenone.
  • Gastrointestinal Drugs domperidone, naloxegol.
  • Lipid Regulating Drugs lomitapide, lovastatin, simvastatin.
  • Urologic Drugs fesoterodine, in subjects with moderate to severe renal impairment, or moderate to severe hepatic impairment.
  • Solifenacin, in subjects with severe renal impairment or moderate to severe hepatic impairment.
  • Miscellaneous Drugs and Other Substances colchicine, in subjects with renal or hepatic impairment, eliglustat.

 

There is limited information regarding cross-hypersensitivity between Itraconazole and other Azole Antifungal agents. Caution should be used in prescribing ITRACONAZOLE capsules to patients with hypersensitivity to other Azoles.